Lincomycin Hydrochloride Injection

Founded in 1970 and listed on the Shanghai Stock Exchange since 2017, CISEN PHARMACEUTICAL CO., LTD. manufactures a broad portfolio of finished dosage products spanning anti-tumor, antibiotic and antiviral, cardiovascular, respiratory, digestive, anesthetic, vitamin and mineral, antiparasitic, hormone-related, and other therapeutic categories, covering the full industry chain from API to finished product for one-stop customer sourcing. The company established an R&D subsidiary in India in 2018, passed a US FDA cGMP audit in 2019, and received FDA approval for its Esomeprazole Magnesium Delayed Release Capsule in 2021; it offers CMO contract manufacturing on FOB terms (30% advance, 70% before shipment, T/T) to customers across North America, Central/South America, Western and Eastern Europe, Australasia, Asia, the Middle East, and Africa. Cisen is recognized for its brand, international certifications, experienced R&D staff, broad product line, and quality-driven service.